Healthcare / Medical DevicesNasdaqCM
$4.70
-0.30 (-6.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $-9.1M · quality 39.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
14/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$62M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-327.1%
↓Gross Margin
45.4%
↓Debt/Equity
0.81
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-48.0%
FCF / Net income
0.43x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $18.9M · net income $-21.1M · FCF $-9.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $18.9M | $18.9M | $4.9M | $40355.00 | — |
| Net Income | $-21.1M | $-21.1M | $-9.0M | $-6.1M | $-2.8M |
| EBITDA | $-18.3M | $-18.3M | $-4.3M | $-5.1M | $-2.3M |
| EPS | -2.01 | -2.01 | -0.71 | -1.92 | -0.87 |
| Gross Margin | 45.4% | 45.4% | 54.1% | -234.5% | — |
| Operating Margin | -23.4% | -23.4% | -249.6% | -12409.8% | — |
| Net Margin | -111.4% | -111.4% | -184.2% | -15113.2% | — |
| Balance Sheet | |||||
| Debt/Equity | 0.81 | 0.81 | -1.04 | -1.80 | 0.03 |
| Current Ratio | 2.49 | 2.49 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-9.1M | $-9.1M | $-10.1M | $-2.7M | $-1.3M |
| Returns | |||||
| ROE | -327.1% | -327.1% | 94.2% | 114.8% | -9.7% |
| Valuation | |||||
| P/B | 7.64 | 7.64 | — | — | 51.62 |
| Growth & Yield | |||||
| Revenue Growth | 287.9% | 287.9% | 11990.2% | — | — |
| EPS Growth | -183.1% | -183.1% | 63.0% | -120.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-61.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.71 → -2.01
Residual
-61.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.